SCOPUS 정보 검색 플랫폼

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 449-452

In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US

(3) Dansereau, Richard J a Crail, Debbie J a Perkins, Alan C b

a PROCTER AND GAMBLE PHARMACEUTICALS (United States)

b UNIVERSITY OF NOTTINGHAM (United Kingdom)

Author keywords

Alendronate sodium tablets; Disintegration time; United states copies generics

Indexed keywords

ALENDRONIC ACID; GENERIC DRUG;

ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG SAFETY; DRUG TOLERABILITY; EXPOSURE; GASTROINTESTINAL IRRITATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; SINGLE DRUG DOSE; STANDARD; TABLET COMPRESSION; TABLET FORMULATION; UNITED STATES; CHEMISTRY; TABLET;

ALENDRONATE; DRUGS, GENERIC; TABLETS; UNITED STATES;

EID: 64249096693 PISSN: 03007995 EISSN: 14734877 Source Type: Journal
DOI: 10.1185/03007990802648903 Document Type: Article

Times cited : (15)

References (16)

1
- 0028851590
- Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, the Alendronate Phase III Osteoporosis Treatment Study Group
- Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-1443
- (1995) N Engl J Med , vol.333 , pp. 1437-1443
- Liberman, U.A.¹ Weiss, S.R.² Broll, J.³

2
- 0004851872
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
- DOI 10.1016/S0140-6736(96)07088-2
- Black DM, Cummings SR, Karpf D, et al. Randomised trial effects of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trail Research Group. Lancet 1996;348:1535-1541 (Pubitemid 26411651)
- (1996) Lancet , vol.348 , Issue.9041 , pp. 1535-1541
- Black, D.M.¹ Cummings, S.R.² Karpf, D.B.³ Cauley, J.A.⁴ Thompson, D.E.⁵ Nevitt, M.C.⁶ Bauer, D.C.⁷ Genant, H.K.⁸ Haskell, W.L.⁹ Marcus, R.¹⁰ Ott, S.M.¹¹ Torner, J.C.¹² Quandt, S.A.¹³ Reiss, T.F.¹⁴ Ensrud, K.E.¹⁵

3
- 12144289279
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
- DOI 10.1056/NEJMoa030897
- Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199 (Pubitemid 38339363)
- (2004) New England Journal of Medicine , vol.350 , Issue.12 , pp. 1189-1199
- Bone, H.G.¹ Hosking, D.² Devogelaer, J.-P.³ Tucci, J.R.⁴ Emkey, R.D.⁵ Tonino, R.P.⁶ Rodriguez-Portales, J.A.⁷ Downs, R.W.⁸ Gupta, J.⁹ Santora, A.C.¹⁰ Liberman, U.A.¹¹

4
- 0028606037
- Pamidronate: An unrecognized problem in gastrointestinal tolerability
- Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-322
- (1994) Osteoporosis Int , vol.4 , pp. 320-322
- Lufkin, E.G.¹ Argueta, R.² Whitaker, M.D.³

5
- 0010496839
- Esophagitis associated with the use of alendronate
- deGroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021
- (1996) N Engl J Med , vol.335 , pp. 1016-1021
- DeGroen, P.C.¹ Lubbe, D.F.² Hirsch, L.J.³

6
- 0020662199
- Pill-induced esophageal injury. Case reports and review of the medical literature
- DOI 10.1007/BF01315148
- Kikendall JW, Friedman AC, Oyewole MA, et al. Pill-induced esophageal injury: case reports and review of the medical literature. Dig Dis Sci 1983;28:174-182 (Pubitemid 13190098)
- (1983) Digestive Diseases and Sciences , vol.28 , Issue.2 , pp. 174-182
- Kikendall, J.W.¹ Friedman, A.C.² Oyewole, M.A.³

7
- 0025932213
- Pill-induced esophageal injury
- Kikendall J. Pill-induced esophageal injury. Gastroenterol Clin North Am 1991;20:835-846
- (1991) Gastroenterol Clin North Am , vol.20 , pp. 835-846
- Kikendall, J.¹

8
- 0022470882
- Where do all the tablets go?
- 1986
- Spiller R. 1986. Where do all the tablets go? Gut 1986; 27:879-885
- (1986) Gut , vol.27 , pp. 879-885
- Spiller, R.¹

9
- 0032886956
- Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations
- DOI 10.1016/S0378-5173(99)00172-6, PII S0378517399001726
- Perkins AC, Wilson CG, Frier M, et al. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharm 1999;186:169-175 (Pubitemid 29459044)
- (1999) International Journal of Pharmaceutics , vol.186 , Issue.2 , pp. 169-175
- Perkins, A.C.¹ Wilson, C.G.² Frier, M.³ Vincent, R.M.⁴ Blackshaw, P.E.⁵ Dansereau, R.J.⁶ Juhlin, K.D.⁷ Bekker, P.J.⁸ Spiller, R.C.⁹

10
- 0029793118
- The influence of ageing on oesophageal motility after ingestion of liquids with different viscosities
- Ferriolli E, Dantas RO, Oliveira RB, et al. The influence of ageing on oesophageal motility after ingestion of liquids with different viscosities. Eur J Gatoenterol Hepatol 1996; 8:793-798 (Pubitemid 26275699)
- (1996) European Journal of Gastroenterology and Hepatology , vol.8 , Issue.8 , pp. 793-798
- Ferriolli, E.¹ Dantas, R.O.² Oliveira, R.B.³ Braga, F.J.N.H.⁴

11
- 67649327580
- United States Pharmacopeia. United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, USA
- United States Pharmacopeia. Alendronate Sodium and Alendronic Acid Tablets, 30th edn, United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, USA, 2007:1318-1319
- (2007) Alendronate Sodium and Alendronic Acid Tablets, 30th Edn , pp. 1318-1319

12
- 42549171198
- In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications
- Dansereau R, Crail D, Perkins AC. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008;24:1137-1145
- (2008) Curr Med Res Opin , vol.24 , pp. 1137-1145
- Dansereau, R.¹ Crail, D.² Perkins, A.C.³

13
- 67649369708
- United States Pharmacopeia. United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, USA
- United States Pharmacopeia. Disintegration, 30th edn, United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, USA, 2007:276-277
- (2007) Disintegration, 30th Edn , pp. 276-277

14
- 42549151913
- European Pharmacopoeia.
- European Pharmacopoeia. General Notices, 5th edn, Vol.1, 2005;627
- (2005) General Notices, 5th Edn , vol.1 , pp. 627

15
- 67649357334
- FDA Center for Drug Evaluation and Research (CDER), April Available at: [Last accessed 20 June 2008]
- Guidance for Industry, Orally Disintegrating Tablets. FDA Center for Drug Evaluation and Research (CDER), April 2007. Available at: www.fda.gov/cder/ guidance/5909dft.htm [Last accessed 20 June 2008]
- (2007) Guidance for Industry, Orally Disintegrating Tablets

16
- 84861603409
- Merck & Co. Inc., Whitehouse Station, NJ. Available at: [Last accessed 20 June 2008]
- Fosamax® (alendroante sodium) tablet and oral solution. Merck & Co. Inc., Whitehouse Station, NJ. Available at: www.merck. com/product/usa/pi- circulars/f/products-f.html [Last accessed 20 June 2008]
- Fosamax® (Alendroante Sodium) Tablet and Oral Solution

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.